# Villa Maria Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/villa-maria-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 115 |
| Citations | 26,064 |
| City | Kalungu |
| Country | UG |
| Description | Villa Maria Hospital is a research organisation in Kalungu, UG. OpenAlex records 1,115 works and 26,064 citations for it. 460 researchers list it as their most recent affiliation. |
| Homepage | http://villamariahospital.org/ |
| OpenAlex ID | https://openalex.org/I2801982740 |
| Researchers | 460 |
| ROR ID | https://ror.org/024yt9656 |
| Type | healthcare |
| Wikidata ID | https://www.wikidata.org/wiki/Q16902740 |
| Works | 1,115 |

## University papers

Showing 12 of 16.

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study](https://scholariq.org/papers/pembrolizumab-monotherapy-for-previously-treated-metastatic-triple-negative/)
- [Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial](https://scholariq.org/papers/elacestrant-oral-selective-estrogen-receptor-degrader-versus-standard-endocrine/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple/)
- [A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds](https://scholariq.org/papers/a-biobank-of-breast-cancer-explants-with-preserved-intra-tumor-heterogeneity-to/)
- [PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer](https://scholariq.org/papers/pi3k-inhibition-results-in-enhanced-estrogen-receptor-function-and-dependence-in/)

## University top topics

Showing 8 of 25.

- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Infective Endocarditis Diagnosis and Management](https://scholariq.org/topics/infective-endocarditis-diagnosis-and-management/)
- [Cardiac and Coronary Surgery Techniques](https://scholariq.org/topics/cardiac-and-coronary-surgery-techniques/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.